Novel anti-amyloid drug BAN2401 enters Phase III trial in Alzheimer’s patients
BAN2401 will be tested in various stages of Alzheimer’s disease progression to assess if it can slow the progression of cognitive decline.
List view / Grid view
News
Plant-based COVID-19 vaccine enters Phase I trials
The vaccine containing a recombinant coronavirus virus-like particles (CoVLP) will be tested in three different doses and with two different adjuvants.
UK’s SARS-CoV-2 vaccine candidate is safe and induces antibody and T cell response
Data released from the Phase I/II trial of the ChAdOx1 COVID-19 vaccine candidate suggests it elicits an immune response with no adverse effects.
Partnership to fight COVID-19 medication counterfeiting and advance blockchain solutions
The alliance between Chronicled and Deloitte intends to enhance security and efficiency in the pharma supply chain by bring to market new blockchain-powered solutions.
COVID-19 vaccine safely induces immune response in Chinese trial
Investigators report CanSino Biologics’ Ad5-nCoV vaccine induced antibody production with mild to moderate side effects in patients.
UK government secures early access to 90 million doses of COVID-19 vaccines
The government has entered partnerships with Pfizer and Valneva to secure doses of several promising COVID-19 vaccines and secured COVID-19 neutralising antibody treatments from AstraZeneca.
Inhaled interferon beta therapy shows promise in COVID-19 trial
SNG001 diminished the risk of COVID-19 patients developing severe symptoms, reduced breathlessness and improved recovery rates.
Johnson & Johnson to start COVID-19 vaccine trials next week
The company will start enrolment to the Ad26.COV2-S vaccine trial next week, it anticipates initial results in September.
![Novartis logo Novartis building in Stein, Switzerland [Credit: Taljat David shutterstock.com]](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/novartis-image-300x278.jpg)
![Novartis logo Novartis building in Stein, Switzerland [Credit: Taljat David shutterstock.com]](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/novartis-image-scaled-e1594985022657.jpg)
Novartis launches not-for-profit COVID-19 medications portfolio
The portfolio will be offered to low- and lower-middle-income countries to help financially strained healthcare systems care for COVID-19 patients.
Global antimicrobial resistance fund to support development of innovative antibiotics
The fund has already raised $1 billion to support clinical research of novel antibiotics and intends to bring up to four new antibiotics to market by 2030.
Rotigotine improves cognitive function in Alzheimer’s patients
In a study of 94 patients with mild-to-moderate Alzheimer’s disease, rotigotine improved frontal lobe executive function and enabled patients to independently perform daily activities.
COVID-19 vaccine candidate gets green light for trial in China
The COVID-19 vaccine candidate, BNT162b1, has been approved for clinical trial registration by China's National Medical Products Administration (NMPA).
Experimental COVID-19 vaccine mRNA-1273 is safe and elicits response
Interim analysis of the Phase I trial data from 45 patients indicates mRNA-1273 can drive the production of antibodies targeting the SARS-CoV-2 spike protein.
Tocilizumab lowers risk of death for critical COVID-19 patients on ventilators, finds study
Patients who received tocilizumab in the retrospective, single-centre study were 45 percent less like to die and more likely to come off ventilation within 28 days.
Oral bacteriotherapy improved outcomes in COVID-19 patients
Clinical trial testing a live biotherapeutic in hospitalised COVID-19 patients suggests the bacteriotherapy could be promising.
